Amgen's new research and development facility in San Francisco. (courtesy photo) Shares of Thousand Oaks-based Amgen gained 12% on May 3, one day after the company disclosed its earnings for the first quarter of 2024 and highlighted the excitement around its weight-loss drug. During the company’s earnings call, Amgen CEO Bob Bradway commented on their
Santa Barbara-based American Riviera Bank saw net income take a slight dip in the first quarter of 2024. Announced April 24, ARB noted net income of $2.2 million for the quarter ended March 31, down from $3 million in the same quarter a year ago. According to a press release, the dip in net income
Sierra Bancorp, the parent company of Bank of the Sierra, announced its results for the first quarter of 2024 on April 23, noting that consolidated net income was at $9.3 million for the quarter, up from $8.8 million in the same quarter a year ago. According to the financial statements, the “favorable variance” in net
Conejo Valley-based Acelyrin, a clinical, pre-revenue biotechnology company, reported its financial results for the full year 2023 on March 28. According to the March 28 report, the company’s net loss for the full year ended Dec. 31 was $381.6 million, compared to $64.8 million for 2022. The company primarily saw expenses increase in research and
Thousand Oaks-based Atara Biotherapeutics reported financial results for the fourth quarter and full year 2023 along with recent business highlights and key upcoming milestones for 2024 on March 28. Atara reported a net loss of $60.5 million or 56 cents per share in the fourth quarter of 2023 along with a net loss of $276.1 million